---
figid: PMC3092522__nihms289124f2
figlink: /pmc/articles/PMC3092522/figure/F2/
number: F2
caption: (A) Lapatinib is a dual EGF receptor (EGFR)/HER2 tyrosine kinase inhibitor
  approved for use in trastuzumab-refractory patients. Neratinib is an irreversible
  tyrosine kinase inhibitor of EGFR/HER2. (B) Pertuzumab, a monoclonal antibody to
  HER2, binds to HER2 at a distinct epitope from where trastuzumab binds and prevents
  ligand-induced heterodimerization with HER3. Dysregulated activation of the PI3K–AKT–mTOR
  pathway can mediate trastuzumab resistance, and molecular therapies aimed at directly
  inhibiting PI3K, AKT and mTOR are therefore in development. (C) HSP90 inhibitors
  promote HER2 degradation by blocking the activity of HSP90, a chaperone protein
  that protects HER2 from proteasomal degradation. (D) TDM-1, the antibody–drug conjugate
  of trastuzumab and maytansine, allows for delivery of a potent microtubule inhibitor
  selectively into HER2-overexpressing cells.
pmcid: PMC3092522
papertitle: 'HER2-amplified breast cancer: mechanisms of trastuzumab resistance and
  novel targeted therapies.'
reftext: Devika Gajria, et al. Expert Rev Anticancer Ther. ;11(2):263-275.
pmc_ranked_result_index: '115763'
pathway_score: 0.9787785
filename: nihms289124f2.jpg
figtitle: 'HER2-amplified breast cancer: mechanisms of trastuzumab resistance and
  novel targeted therapies'
year: ''
organisms:
- Homo sapiens
ndex: 206ed19c-debd-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3092522__nihms289124f2.html
  '@type': Dataset
  description: (A) Lapatinib is a dual EGF receptor (EGFR)/HER2 tyrosine kinase inhibitor
    approved for use in trastuzumab-refractory patients. Neratinib is an irreversible
    tyrosine kinase inhibitor of EGFR/HER2. (B) Pertuzumab, a monoclonal antibody
    to HER2, binds to HER2 at a distinct epitope from where trastuzumab binds and
    prevents ligand-induced heterodimerization with HER3. Dysregulated activation
    of the PI3K–AKT–mTOR pathway can mediate trastuzumab resistance, and molecular
    therapies aimed at directly inhibiting PI3K, AKT and mTOR are therefore in development.
    (C) HSP90 inhibitors promote HER2 degradation by blocking the activity of HSP90,
    a chaperone protein that protects HER2 from proteasomal degradation. (D) TDM-1,
    the antibody–drug conjugate of trastuzumab and maytansine, allows for delivery
    of a potent microtubule inhibitor selectively into HER2-overexpressing cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R5
  - HSP90AB1
  - TRAP1
  - ERBB3
  - AKT1
  - PIK3CD
  - PIK3CA
  - ERBB2
  - PIK3R6
  - HSP90B1
  - PIK3CB
  - PIK3R4
  - AKT3
  - MTOR
  - PIK3CG
  - PIK3R3
  - DMPK
  - AKT2
  - Temsirolimus
  - Neratinib
  - BEZ235
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: hsp90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90AB1
  entrez: '3326'
- word: hsp90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: TRAP1
  entrez: '10131'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: hsp90
  symbol: HSP90
  source: bioentities_symbol
  hgnc_symbol: HSP90B1
  entrez: '7184'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: DM1
  symbol: DM1
  source: hgnc_prev_symbol
  hgnc_symbol: DMPK
  entrez: '1760'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Neratinib
  source: MESH
  identifier: C487932
- word: BEZ235
  source: MESH
  identifier: C531198
diseases: []
figid_alias: PMC3092522__F2
redirect_from: /figures/PMC3092522__F2
figtype: Figure
---
